Shibing Deng1, Xuying Yi2, Zhiming Tian1. 1. Department of Internal Medicine, The First Clinical Medical College of Yangtze University. 2. Department of Internal Medicine, The First People's Hospital of Jingzhou, Jingzhou, Hubei, China.
Abstract
BACKGROUND: Percutaneous coronary intervention with the new generation drug eluting stents (DES) is 1 among the revascularization procedures required to treat patients with coronary artery disease (CAD). Since late stent thrombosis and silent myocardial infarction are highly associated with type 2 diabetes mellitus (T2DM), an analysis comparing the newer generation DES in this specific subgroup of patients would be scientifically relevant.In this analysis, we aimed to systematically compare the cardiovascular outcomes observed with the ultrathin bioresorbable polymer sirolimus eluting stents (SES) versus thin, durable polymer everolimus eluting stents (EES) following percutaneous coronary intervention in patients with T2DM. METHODS: Through online databases, relevant studies comparing ultrathin bioresorbable polymer SES versus the durable polymer EES were carefully searched. The cardiovascular outcomes were assessed during a follow-up time period of 1 year and more than 1 year (1-5 years) respectively. This meta-analysis was carried out by the latest version of the RevMan software. Following analysis, the results were represented by odds ratios (OR) with 95% confidence intervals (CI). RESULTS: A total number of 1967 patients with T2DM were included in this analysis. During a 1 year follow-up time period, target lesion failure (TLF) (OR: 0.59, 95% CI: 0.34-1.02; P = .06, target vessel revascularization (TVR) (OR: 0.97, 95% CI: 0.55-1.70; P = .91) and target lesion revascularization (TLR) (OR: 0.91, 95% CI: 0.44-1.87; P = .79) were similarly observed with ultrathin bioresorbable polymer SES versus the thin, durable polymer EES in these patients with T2DM. Other cardiovascular outcomes including myocardial infarction (MI), major adverse cardiac events, all-cause mortality (OR: 0.72, 95% CI: 0.37-1.40; P = .34), cardiac death and stent thrombosis (OR: 0.85, 95% CI: 0.45-1.62; P = .63) were also similarly observed with these 2 types of new stents. During a follow-up time period above 1 year (1-5 years), still no significant difference was observed in TLF, TVR, TLR, major adverse cardiac events, MI, all-cause mortality, cardiac death and stent thrombosis (OR: 0.62, 95% CI: 0.33-1.16; P = .14). CONCLUSIONS: The ultrathin bioresorbable polymer SES were similar to the durable polymer EES in these patients with T2DM. These 2 types of new generation stents were comparable in terms of cardiovascular outcomes. Hence, they might be recommended in patients with T2DM. Upcoming trials should be able to confirm this hypothesis.
BACKGROUND: Percutaneous coronary intervention with the new generation drug eluting stents (DES) is 1 among the revascularization procedures required to treat patients with coronary artery disease (CAD). Since late stent thrombosis and silent myocardial infarction are highly associated with type 2 diabetes mellitus (T2DM), an analysis comparing the newer generation DES in this specific subgroup of patients would be scientifically relevant.In this analysis, we aimed to systematically compare the cardiovascular outcomes observed with the ultrathin bioresorbable polymer sirolimus eluting stents (SES) versus thin, durable polymer everolimus eluting stents (EES) following percutaneous coronary intervention in patients with T2DM. METHODS: Through online databases, relevant studies comparing ultrathin bioresorbable polymer SES versus the durable polymer EES were carefully searched. The cardiovascular outcomes were assessed during a follow-up time period of 1 year and more than 1 year (1-5 years) respectively. This meta-analysis was carried out by the latest version of the RevMan software. Following analysis, the results were represented by odds ratios (OR) with 95% confidence intervals (CI). RESULTS: A total number of 1967 patients with T2DM were included in this analysis. During a 1 year follow-up time period, target lesion failure (TLF) (OR: 0.59, 95% CI: 0.34-1.02; P = .06, target vessel revascularization (TVR) (OR: 0.97, 95% CI: 0.55-1.70; P = .91) and target lesion revascularization (TLR) (OR: 0.91, 95% CI: 0.44-1.87; P = .79) were similarly observed with ultrathin bioresorbable polymer SES versus the thin, durable polymer EES in these patients with T2DM. Other cardiovascular outcomes including myocardial infarction (MI), major adverse cardiac events, all-cause mortality (OR: 0.72, 95% CI: 0.37-1.40; P = .34), cardiac death and stent thrombosis (OR: 0.85, 95% CI: 0.45-1.62; P = .63) were also similarly observed with these 2 types of new stents. During a follow-up time period above 1 year (1-5 years), still no significant difference was observed in TLF, TVR, TLR, major adverse cardiac events, MI, all-cause mortality, cardiac death and stent thrombosis (OR: 0.62, 95% CI: 0.33-1.16; P = .14). CONCLUSIONS: The ultrathin bioresorbable polymer SES were similar to the durable polymer EES in these patients with T2DM. These 2 types of new generation stents were comparable in terms of cardiovascular outcomes. Hence, they might be recommended in patients with T2DM. Upcoming trials should be able to confirm this hypothesis.
Authors: Thomas Pilgrim; Raffaele Piccolo; Dik Heg; Marco Roffi; David Tüller; Olivier Muller; Igal Moarof; George C M Siontis; Stéphane Cook; Daniel Weilenmann; Christoph Kaiser; Florim Cuculi; Lukas Hunziker; Franz R Eberli; Peter Jüni; Stephan Windecker Journal: Lancet Date: 2018-08-28 Impact factor: 79.321
Authors: Kyohei Yamaji; Thomas Zanchin; Christian Zanchin; Stefan Stortecky; Konstantinos C Koskinas; Lukas Hunziker; Fabien Praz; Stefan Blöchlinger; Christina Moro; Aris Moschovitis; Christian Seiler; Marco Valgimigli; Michael Billinger; Thomas Pilgrim; Dik Heg; Stephan Windecker; Lorenz Räber Journal: Circ Cardiovasc Interv Date: 2018-09 Impact factor: 6.546
Authors: Ariel Roguin; David E Kandzari; Erez Marcusohn; Jacques J Koolen; Gheorghe Doros; Joseph M Massaro; Hector M Garcia-Garcia; Johan Bennett; Elie G Gharib; Donald E Cutlip; Ron Waksman Journal: Circ Cardiovasc Interv Date: 2018-10 Impact factor: 6.546
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: Alexandra J Lansky; Adnan Kastrati; Elazer R Edelman; Helen Parise; Vivian G Ng; John Ormiston; William Wijns; Robert A Byrne Journal: Am J Cardiol Date: 2015-12-07 Impact factor: 2.778
Authors: Stephan Windecker; Stefan Stortecky; Giulio G Stefanini; Bruno R da Costa; Bruno R daCosta; Anne Wilhelmina Rutjes; Marcello Di Nisio; Maria G Silletta; Maria G Siletta; Ausilia Maione; Fernando Alfonso; Peter M Clemmensen; Jean-Philippe Collet; Jochen Cremer; Volkmar Falk; Gerasimos Filippatos; Christian Hamm; Stuart Head; Arie Pieter Kappetein; Adnan Kastrati; Juhani Knuuti; Ulf Landmesser; Günther Laufer; Franz-Joseph Neumann; Dimitri Richter; Patrick Schauerte; Miguel Sousa Uva; David P Taggart; Lucia Torracca; Marco Valgimigli; William Wijns; Adam Witkowski; Philippe Kolh; Peter Jüni; Peter Juni Journal: BMJ Date: 2014-06-23